Investor Presentation
ACI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Archean Chemical reported FY26 consolidated revenue of Rs. 11,080 million (up 3% YoY), but Q4FY26 saw a 13% decline to Rs. 3,063 million due to Industrial Salt moderation and geopolitical disruptions impacting exports (78% of revenue). Industrial Salt grew 10% to Rs. 7,286 million on strong volume of 4.25 million tons, while Bromine revenue fell 13% to Rs. 3,084 million due to technical downtime. Consolidated EBITDA dropped significantly year-on-year due to logistics cost pressures (50% increase in fuel costs, route disruptions) and losses at subsidiaries Acume Chemicals (-98.3mn EBITDA) and Idealis Mudchemie (-47.8mn). The company has diversified into semiconductors via SiCSem subsidiary, executed Fiscal Support Agreement with India Semiconductor Mission on May 11, 2026, and holds 22.24% stake in UK's Clas-Sic Wafer Fab for SiC power devices.
The stock faces near-term margin pressure from logistics costs and subsidiary losses, but the semiconductor foray and new product pipeline (Bromine Derivatives breakeven targeted FY27) could drive growth. The Rs. 2.50 dividend provides some investor compensation.